
Lyell Immunopharma Q3 Net Loss $45.5M; Raises $80M; Ronde-cel Data Positive
Lyell Immunopharma announced its third quarter 2026 financial results, reporting a net loss of $45.5 million, an increase from $38.8 million in the prior year period, primarily due to higher research and development expenses. The company also highlighted significant business updates, including positive clinical data for its ronde-cel therapy, with an 91% overall response rate in the PiNACLE pivotal trial. Lyell secured $80.0 million in private placement financing, which, combined with existing cash reserves of $194.0 million, is expected to fund operations into 2028. The company is on track for pivotal data and BLA submission for ronde-cel in the second half of 2027 and expects further clinical data for LYL273 in 2027.
Key Highlights
- Lyell Immunopharma reported a Q3 2026 net loss of $45.5 million, an increase from $38.8 million in Q3 2025.
- Announced $80.0 million private placement financing to extend cash runway into 2028.
- Updated clinical data for ronde-cel showed 91% overall response rate and 77% complete response rate in 3L+ PiNACLE trial.
- PiNACLE pivotal data expected mid-2027, with BLA submission targeted for second half of 2027.
- Completed technology transfer of LYL273 to LyFE Manufacturing Center; additional data expected in 2027.
- Q3 2026 R&D expenses increased to $40.9 million from $28.2 million in Q3 2025.
- Cash, cash equivalents, and marketable securities stood at $194.0 million as of September 30, 2026.
Price Impact
More from LYEL